“I think some of the new treatments will probably move the needle a little bit more in terms of treating this indication.” Ip MS. Update on the current treatment of diabetic retinopath ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

The collaboration will focus on preventive solutions, workshops, and public awareness. King Faisal Specialist Hospital and ...

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

“There’s very clear evidence that screening prevents vision loss,” says Roomasa Channa, a retina specialist at the University of Wisconsin-Madison in the US. In the US barriers include cost, ...

The risk for nonproliferative diabetic retinopathy progression was similar ... during a mean follow-up period of 8 months receiving treatment, the risk for incident NPDR did not differ across ...

The implementation of AIDRSS offers transformative implications for DR screening in India, particularly in rural and ...

Insurance coverage for intravitreal injections, an essential treatment for diabetic retinopathy, depends on the specific terms and conditions of an individual’s health insurance policy.

These fragile new vessels leak fluid that collects ... until significant damage occurs. What are the treatment options available for diabetic retinopathy? Early stages may only require ongoing ...